全球前葡萄膜炎治疗市场规模、份额和成长分析：按治疗和分销管道 - 行业预测（2024-2031）

2022年全球前葡萄膜炎治疗市场规模将为3.5亿美元，从2023年的3710亿美元增长到2031年的5913.2亿美元，在预测期内（2024年-2031年）预计复合年增长率为6 %。

传播的一个主要驱动因素是前葡萄膜炎病例的迅速增加，其特征是眼睛葡萄膜前部的发炎。治疗主要涉及皮质类固醇和免疫抑制剂，通常是皮质类固醇眼药水。多种潜在疾病可诱发前​​葡萄膜炎并导致其流行。皮质类固醇的处方取决于葡萄膜炎的类型，因为它们会影响免疫系统。随着世界老化，这种疾病的脆弱性增加。以修美乐 (Humira)的核准为代表的治疗方法创新，以及意识提高、眼部感染率和有利的法规环境等因素，预计将推动成长。与前葡萄膜炎相关的併发症包括眼压升高和皮质类固醇治疗的潜在副作用，导致青光眼和白内障等疾病，因此没有有效的治疗方法来预防不可逆转的视力丧失，这凸显了有效管理策略的必要性。

目录

执行摘要

• 市场概况
• 命运之轮

调查方法

• 资讯采购
• 次要/一级资讯来源
• 市场规模估算
• 市场假设与限制

母市场分析

• 市场概况
• 市场规模
• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务

主要市场考察

• 技术分析
• 价格分析
• 供应链分析
• 价值链分析
• 市场生态系统
• 智慧财产权分析
• 贸易分析
• Start-Ups分析
• 原料分析
• 创新矩阵
• 研发线产品分析
• 总体经济指标
• 主要投资分析
• 关键成功因素
• 竞争程度

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 监管环境
• 波特的分析
• 对未来中断的特殊考虑

前葡萄膜炎治疗的全球市场：依治疗分类

• 市场概况
• 皮质类固醇
• 循环麻木剂
• 抗TNF剂
• 免疫抑制剂

全球前葡萄膜炎治疗市场：按分销管道

• 市场概况
• 医院
• 零售
• 网路药房

全球前葡萄膜炎治疗市场规模：按地区

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2021年）
• 主要市场参与者所采取的策略
• 关键成功策略
• 近期市集活动
• 主要企业市场占有率（2021年）

主要企业简介

• Novartis AG
• Allergan（now part of AbbVie Inc.）
• Bausch Health Companies Inc.
• Santen Pharmaceutical Co., Ltd.
• Alcon Inc.
• EyePoint Pharmaceuticals
• AbbVie Inc.
• Sun Pharmaceutical Industries Ltd.
• Valeant Pharmaceuticals International（now Bausch Health Companies Inc.）
• Hikma Pharmaceuticals PLC
• Teva Pharmaceutical Industries Ltd.
• Johnson & Johnson
• AbbVie Inc.
• Bausch Health Companies Inc.
• Mylan NV
• Akorn Pharmaceuticals
• Ocular Therapeutix, Inc.
• Clearside Biomedical, Inc.
• Topcon Corporation
• Carl Zeiss Meditec AG

Global Anterior Uveitis Treatment Market size was valued at USD 350 million in 2022 and is poised to grow from USD 371 billion in 2023 to USD 591.32 billion by 2031, growing at a CAGR of 6% during the forecast period (2024-2031).

The surge in cases of anterior uveitis is a significant driving force behind its expansion, characterized by inflammation in the front portion of the eye's uvea. Management primarily involves corticosteroids and immunosuppressive agents, often administered through corticosteroid eye drops. Various underlying conditions can trigger anterior uveitis, contributing to its prevalence. Prescription of corticosteroids is contingent upon the type of uveitis due to their impact on the immune system. With an aging global population, the vulnerability to this condition increases. Innovations in treatments, exemplified by Humira's approval, are expected to fuel growth, alongside factors such as heightened awareness, ocular infection rates, and favorable regulatory environments. Complications associated with anterior uveitis include elevated intraocular pressure and potential adverse reactions to corticosteroid treatment, leading to conditions like glaucoma and cataracts, emphasizing the need for effective management strategies to prevent irreversible blindness.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Anterior Uveitis Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Anterior Uveitis Treatment Market Segmental Analysis

The global anterior uveitis treatment market is segmented on the basis of treatment, distribution channel, region. By treatment, the market is segmented into corticosteroids, cycloplegic agents, anti-tnf agents, immunosuppressants. By distribution channel, the market is segmented into hospital, retail, online pharmacies. By region, the market is segmented into North America, Europe, Latin America, Asia- Pacific, Middle East and Africa.

Drivers of the Global Anterior Uveitis Treatment Market

The rising prevalence of anterior uveitis worldwide, along with the expanding elderly population, serves as a key factor propelling market growth. With the disease becoming more widespread, there is a heightened demand for efficient treatment options.

Restraints in the Global Anterior Uveitis Treatment Market

Certain treatment methods, notably corticosteroids, have the potential to induce undesirable outcomes such as elevated intraocular pressure, cataracts, and glaucoma, which can constrain their prolonged application and impact patient adherence.

Market Trends of the Global Anterior Uveitis Treatment Market

Exploring gene therapies offers hope in tackling the underlying triggers of anterior uveitis through the precise targeting of particular genetic mutations or irregularities linked to this condition.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Anterior Uveitis Treatment Market by Treatment

• Market Overview
• Corticosteroids
• Cycloplegic Agents
• Anti-TNF Agents
• Immunosuppressants

Global Anterior Uveitis Treatment Market by Distribution Channel

• Market Overview
• Hospital
• Retail
• Online Pharmacies

Global Anterior Uveitis Treatment Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Allergan (now part of AbbVie Inc.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Santen Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alcon Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• EyePoint Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Valeant Pharmaceuticals International (now Bausch Health Companies Inc.)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bausch Health Companies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Akorn Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ocular Therapeutix, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Clearside Biomedical, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Topcon Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Carl Zeiss Meditec AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments